Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on...
December 19, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Ring the Opening Bell at Nasdaq

LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain...
December 15, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
October 16, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
May 19, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
April 30, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans...
January 31, 2025 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chairman and CEO Acquire Shares

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
November 26, 2024 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

LONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
October 30, 2024 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
October 23, 2024 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled,...